SCYNEXIS, Inc. to Present at the 39th Annual Canaccord Genuity Global Growth Conference

Download as PDF

JERSEY CITY, N.J., July 31, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the 39th Annual Canaccord Genuity Global Growth Conference at The InterContinental Boston on Wednesday, August 7, 2019 at 11:30 a.m. ET.

A live webcast of the presentation will be available on the Investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, having discovered and developed more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly known as SCY-078), is a novel IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida, Aspergillus and Pneumocystis species. For more information, visit www.scynexis.com.

CONTACT: 

Investor Relations
Heather Savelle
Argot Partners
Tel: 212-600-1902
heather@argotpartners.com

Media Relations
George E. MacDougall
MacDougall
Tel: 781-235-3093
george@macbiocom.com

Cision View original content:http://www.prnewswire.com/news-releases/scynexis-inc-to-present-at-the-39th-annual-canaccord-genuity-global-growth-conference-300893615.html

SOURCE SCYNEXIS, Inc.

Released July 31, 2019